References for this Rapid Review were identified through searches of PubMed from 2005 to 2007 with the terms “Parkinson's disease”, “PET”, “brain metabolism”, “metabolic networks”, “functional brain imaging”, “biomarkers”, “dopamine”, “treatment”, “SPECT”, “gene therapy”, and “atypical parkinsonism”. Articles were also identified through searches of the references of articles. Only papers published in English were reviewed. Abstracts and reports from meetings were included in the Rapid
Rapid ReviewAssessment of the progression of Parkinson's disease: a metabolic network approach
Section snippets
Biomarkers of Parkinson's disease progression
The need for accurate and comprehensive descriptions of the course of Parkinson's disease is increasingly important as new therapies for this disorder are developed. Knowledge of the rate of disease progression, particularly during the early phases, is essential for the design of clinical trials to evaluate potential neuroprotective treatment strategies. However, such determinations can be difficult when they are made solely on the basis of clinical assessments, and particularly if the
Metabolic changes in the presymptomatic period
Although abnormal network activity is a feature of early Parkinson's disease, precisely when the disease-related metabolic patterns occur is unknown; this is particularly relevant to the study of patients with genetic mutations that predispose them to this disorder. Buhmann and colleagues14 showed increased striatocortical activation with functional MRI during movement in asymptomatic carriers of mutations in PARK2; nigrostriatal dopaminergic dysfunction was also seen in these patients.15 Thus,
Where next?
Several questions about the use of network biomarkers in Parkinson's disease are currently being investigated. Although the major effect of symptomatic treatment on Parkinson's disease-related spatial covariance pattern activity seems to be reversible over 12–18 h,10 the precise time needed for complete washout is not known. This knowledge will be crucial for the design of future neuroprotection trials, particularly of drugs with potential network modulatory effects. Investigations are also
Search strategy and selection criteria
References (26)
- et al.
Neuroimaging and therapeutics in movement disorders
NeuroRx
(2005) - et al.
Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease
Neuroimage
(2006) - et al.
Metabolic brain networks associated with cognitive function in Parkinson's disease
Neuroimage
(2007) - et al.
Correlates of movement initiation and velocity in Parkinson's disease: A longitudinal PET study
Neuroimage
(2007) - et al.
Parkinson's disease: in vivo assessment of disease progression using positron emission tomography
Brain Res Mol Brain Res
(2005) - et al.
Safety and tolerability of AAV-GAD gene therapy for Parkinson's disease: an open label, phase I trial
Lancet
(2007) - et al.
Changes in motor subtype and risk for incident dementia in Parkinson's disease
Mov Disord
(2006) The Parkinson's complex: parkinsonism is just the tip of the iceberg
Ann Neurol
(2006)- et al.
The role of radiotracer imaging in Parkinson disease
Neurology
(2005) - et al.
PET and SPECT
Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging
Proc SPIE: Medical Imaging
Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility
J Cereb Blood Flow Metab
Regional metabolic changes in parkinsonian patients with normal dopaminergic imaging
Mov Disord
Cited by (143)
Subspace corrected relevance learning with application in neuroimaging
2024, Artificial Intelligence in MedicineDiagnosis of Parkinson's disease based on 3D ResNet: The frontal lobe is crucial
2023, Biomedical Signal Processing and ControlCerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism
2022, Neurobiology of DiseaseCitation Excerpt :Characterization of initial cerebral changes associated with these dopaminergic deficits is important to understand the evolution of PD (Blesa et al., 2017; Del Rey et al., 2018). In this sense, positron emission tomography (PET) imaging is routinely applied for clinical evaluation of PD patients using radioligands such as 6-[18F]-fluoro-L-DOPA (18F-DOPA) and [11C]-dihydrotetrabenazine (11C-DTBZ) for evaluating striatal dopaminergic innervation (de la Fuente-Fernandez et al., 2011; Nandhagopal et al., 2011), and 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) as a marker of cerebral glucose consumption for assessing metabolic activity (Eckert et al., 2005, 2007; Hirano et al., 2009; Huang et al., 2007; Niethammer et al., 2012). PET studies have contributed to ascertaining the topography and evolution of dopaminergic loss in PD (de la Fuente-Fernandez et al., 2011), defining compensatory changes (Nandhagopal et al., 2011), and identifying cerebral metabolic patterns associated with motor and cognitive manifestations (Eckert et al., 2005; Hirano et al., 2009; Niethammer et al., 2012).
Neuroimaging approaches to cognition in Parkinson's disease
2022, Progress in Brain ResearchCitation Excerpt :Over two decades ago researchers recognized that regional differences in glucose metabolism, as measured with FDG PET, can be used to distinguish between different forms of parkinsonism (Eidelberg et al., 1993). Since that time, several advanced analysis approaches, such as a spatial covariance method based on principal components analysis (Alexander and Moeller, 1994), have been applied to FDG PET scans to identify disease-specific metabolic patterns in patients with PD and other neurodegenerative disorders (Eckert et al., 2007; Eidelberg, 2009). The degree to which an FDG PET scan shows expression of any given abnormal metabolic patterns can be quantified in individual patients.
Using computerized spiral analysis to evaluate deep brain stimulation outcomes in Parkinson disease
2021, Clinical Neurology and NeurosurgeryCitation Excerpt :This is supported by resting-state functional MRI where enhanced functional connectivity is found between Vim-putamen [24] and Vim-globus pallidus pars interna (GPi) [31] in subjects without predominant tremor. Similarly, positron emission tomography studies have demonstrated hypermetabolism in the ventral thalamus of all PD subjects, not just tremor-predominant subjects [32,33]. Thus, Vim DBS may have more of an overarching “systems” effect [34].